source
- Ultra-low doses could bring costly cancer treatments to more patients in poorer countriesLow-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.STAT · 1mo ago↗ source
- #ASCO26: Yes, Revolution Medicines' pancreatic cancer data are that goodCHICAGO — When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News. “H…Endpoints · 1mo ago↗ source
- #ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer studyCHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus c…